Search results
Results from the WOW.Com Content Network
Treatment-emergent central sleep apnea (TECSA), also known as complex sleep apnea, is a type of sleep apnea that typically develops when a patient starts CPAP therapy for OSA. This can occur when ...
The conditions of hypoxia and hypercapnia, whether caused by apnea or not, trigger additional effects on the body.The immediate effects of central sleep apnea on the body depend on how long the failure to breathe endures, how short is the interval between failures to breathe, and the presence or absence of independent conditions whose effects amplify those of an apneic episode.
In an individual with either central, obstructive or mixed sleep apnea, these low doses may be enough to cause life-threatening irregularities in breathing or collapses in a patient's airways. [87] Use of analgesics and sedatives in these patients postoperatively should therefore be minimized or avoided.
Sleep apnea is a common sleep disorder that affects more than 20 percent of people in the United States. It happens when your breathing temporarily stops while you sleep. Depending on the severity ...
Central hypoventilation syndrome (CHS) is a sleep-related breathing disorder that causes ineffective breathing, apnea, or respiratory arrest during sleep (and during wakefulness in severe cases). CHS can either be congenital (CCHS) or acquired (ACHS) later in life.
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.
Solriamfetol, sold under the brand name Sunosi, is a wakefulness-promoting medication used in the treatment of excessive sleepiness related to narcolepsy and sleep apnea. [1] [5] [6] It is taken by mouth. [1] Common side effects of solriamfetol include headache, nausea, anxiety, and trouble sleeping. [1]
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity -- the first medication ...